Reovirus therapy of tumors with activated Ras pathway - PubMed (original) (raw)
Reovirus therapy of tumors with activated Ras pathway
M C Coffey et al. Science. 1998.
Abstract
Human reovirus requires an activated Ras signaling pathway for infection of cultured cells. To investigate whether this property can be exploited for cancer therapy, severe combined immune deficient mice bearing tumors established from v-erbB-transformed murine NIH 3T3 cells or human U87 glioblastoma cells were treated with the virus. A single intratumoral injection of virus resulted in regression of tumors in 65 to 80 percent of the mice. Treatment of immune-competent C3H mice bearing tumors established from ras-transformed C3H-10T1/2 cells also resulted in tumor regression, although a series of injections were required. These results suggest that, with further work, reovirus may have applicability in the treatment of cancer.
Comment in
- Training viruses to attack cancers.
Pennisi E. Pennisi E. Science. 1998 Nov 13;282(5392):1244-6. doi: 10.1126/science.282.5392.1244. Science. 1998. PMID: 9867627 No abstract available.
Similar articles
- Reovirus as an oncolytic agent against experimental human malignant gliomas.
Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA. Wilcox ME, et al. J Natl Cancer Inst. 2001 Jun 20;93(12):903-12. doi: 10.1093/jnci/93.12.903. J Natl Cancer Inst. 2001. PMID: 11416111 - Oncolytic viral therapy for human pancreatic cancer cells by reovirus.
Etoh T, Himeno Y, Matsumoto T, Aramaki M, Kawano K, Nishizono A, Kitano S. Etoh T, et al. Clin Cancer Res. 2003 Mar;9(3):1218-23. Clin Cancer Res. 2003. PMID: 12631628 - Systemic reovirus therapy of metastatic cancer in immune-competent mice.
Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM, Lee PW. Hirasawa K, et al. Cancer Res. 2003 Jan 15;63(2):348-53. Cancer Res. 2003. PMID: 12543787 - Oligonucleotide treatment of ras-induced tumors in nude mice.
Wickstrom E. Wickstrom E. Mol Biotechnol. 2001 May;18(1):35-55. doi: 10.1385/MB🔞1:35. Mol Biotechnol. 2001. PMID: 11439698 Review. - Reovirus - possible therapy of cancer.
Figova K, Hrabeta J, Eckschlager T. Figova K, et al. Neoplasma. 2006;53(6):457-62. Neoplasma. 2006. PMID: 17167712 Review.
Cited by
- Suppression of IFN-induced transcription underlies IFN defects generated by activated Ras/MEK in human cancer cells.
Christian SL, Zu D, Licursi M, Komatsu Y, Pongnopparat T, Codner DA, Hirasawa K. Christian SL, et al. PLoS One. 2012;7(9):e44267. doi: 10.1371/journal.pone.0044267. Epub 2012 Sep 7. PLoS One. 2012. PMID: 22970192 Free PMC article. - The GM2 glycan serves as a functional coreceptor for serotype 1 reovirus.
Reiss K, Stencel JE, Liu Y, Blaum BS, Reiter DM, Feizi T, Dermody TS, Stehle T. Reiss K, et al. PLoS Pathog. 2012;8(12):e1003078. doi: 10.1371/journal.ppat.1003078. Epub 2012 Dec 6. PLoS Pathog. 2012. PMID: 23236285 Free PMC article. - Naturally occurring reoviruses for human cancer therapy.
Kim M. Kim M. BMB Rep. 2015 Aug;48(8):454-60. doi: 10.5483/bmbrep.2015.48.8.076. BMB Rep. 2015. PMID: 26058397 Free PMC article. Review. - Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
Ilett E, Kottke T, Thompson J, Rajani K, Zaidi S, Evgin L, Coffey M, Ralph C, Diaz R, Pandha H, Harrington K, Selby P, Bram R, Melcher A, Vile R. Ilett E, et al. Gene Ther. 2017 Jan;24(1):21-30. doi: 10.1038/gt.2016.70. Epub 2016 Oct 25. Gene Ther. 2017. PMID: 27779616 Free PMC article. - Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
Mohamed A, Smiley JR, Shmulevitz M. Mohamed A, et al. J Virol. 2020 Jan 31;94(4):e01937-19. doi: 10.1128/JVI.01937-19. Print 2020 Jan 31. J Virol. 2020. PMID: 31776267 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous